Skip to main content
Top
Published in:

Open Access 18-08-2024 | Epilepsy | REVIEW

Presurgical Use of Cenobamate for Adult and Pediatric Patients Referred for Epilepsy Surgery: Expert Panel Recommendations

Authors: Kenneth D. Laxer, Christopher J. Elder, Giancarlo Di Gennaro, Louis Ferrari, Gregory L. Krauss, Jacob Pellinen, William E. Rosenfeld, Vicente Villanueva

Published in: Neurology and Therapy | Issue 5/2024

Login to get access

Abstract

Cenobamate has demonstrated efficacy in patients with treatment-resistant epilepsy, including patients who continued to have seizures after epilepsy surgery. This article provides recommendations for cenobamate use in patients referred for epilepsy surgery evaluation. A panel of six senior epileptologists from the United States and Europe with experience in presurgical evaluation of patients with epilepsy and in the use of antiseizure medications (ASMs) was convened to provide consensus recommendations for the use of cenobamate in patients referred for epilepsy surgery evaluation. Many patients referred for surgical evaluation may benefit from ASM optimization; both ASM and surgical treatment should be individualized. Based on previous clinical studies and the authors’ clinical experience with cenobamate, a substantial proportion of patients with treatment-resistant epilepsy can become seizure-free with cenobamate. We recommend a cenobamate trial and ASM optimization in parallel with presurgical evaluations. Cenobamate can be started before phase two monitoring, especially in patients who are found to be suboptimal surgery candidates. As neurostimulation therapies are generally palliative, we recommend trying cenobamate before vagus nerve stimulation (VNS), deep brain stimulation, or responsive neurostimulation (RNS). In surgically remediable cases (mesial temporal sclerosis, benign discrete lesion in non-eloquent cortex, cavernous angioma, etc.), cenobamate use should not delay imminent surgery; however, a patient may decide to defer or even cancel surgery should they achieve sustained seizure freedom with cenobamate. This decision should be made on an individual, case-by-case basis based on seizure etiology, patient preferences, potential surgical risks (mortality and morbidity), and likely surgical outcome. The addition of cenobamate after unsuccessful surgery or palliative neuromodulation may also be associated with better outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tellez-Zenteno JF, Dhar R, Hernandez-Ronquillo L, Wiebe S. Long-term outcomes in epilepsy surgery: antiepileptic drugs, mortality, cognitive and psychosocial aspects. Brain. 2007;130(Pt 2):334–45.CrossRefPubMed Tellez-Zenteno JF, Dhar R, Hernandez-Ronquillo L, Wiebe S. Long-term outcomes in epilepsy surgery: antiepileptic drugs, mortality, cognitive and psychosocial aspects. Brain. 2007;130(Pt 2):334–45.CrossRefPubMed
2.
go back to reference Sperling MR, Barshow S, Nei M, Asadi-Pooya AA. A reappraisal of mortality after epilepsy surgery. Neurology. 2016;86(21):1938–44.CrossRefPubMed Sperling MR, Barshow S, Nei M, Asadi-Pooya AA. A reappraisal of mortality after epilepsy surgery. Neurology. 2016;86(21):1938–44.CrossRefPubMed
3.
go back to reference Jehi L, Jette N, Kwon CS, Josephson CB, Burneo JG, Cendes F, Sperling MR, Baxendale S, Busch RM, Triki CC, Cross JH, Ekstein D, Englot DJ, Luan G, Palmini A, Rios L, Wang X, Roessler K, Rydenhag B, Ramantani G, Schuele S, Wilmshurst JM, Wilson S, Wiebe S. Timing of referral to evaluate for epilepsy surgery: expert consensus recommendations from the surgical therapies commission of the International League Against Epilepsy. Epilepsia. 2022;63(10):2491–506.CrossRefPubMedPubMedCentral Jehi L, Jette N, Kwon CS, Josephson CB, Burneo JG, Cendes F, Sperling MR, Baxendale S, Busch RM, Triki CC, Cross JH, Ekstein D, Englot DJ, Luan G, Palmini A, Rios L, Wang X, Roessler K, Rydenhag B, Ramantani G, Schuele S, Wilmshurst JM, Wilson S, Wiebe S. Timing of referral to evaluate for epilepsy surgery: expert consensus recommendations from the surgical therapies commission of the International League Against Epilepsy. Epilepsia. 2022;63(10):2491–506.CrossRefPubMedPubMedCentral
4.
go back to reference Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshe SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069–77.CrossRefPubMed Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshe SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069–77.CrossRefPubMed
5.
go back to reference XCOPRI® (cenobamate tablets), for oral use, CV [prescribing information]. Paramus: SK Life Science, Inc.; 2024. XCOPRI® (cenobamate tablets), for oral use, CV [prescribing information]. Paramus: SK Life Science, Inc.; 2024.
6.
go back to reference Ontozry [summary of product characteristics]. Rome: Angelini Pharma S.p.A; 2023. Ontozry [summary of product characteristics]. Rome: Angelini Pharma S.p.A; 2023.
7.
go back to reference Nakamura M, Cho JH, Shin HS, Jang IS. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;855:175–82.CrossRefPubMed Nakamura M, Cho JH, Shin HS, Jang IS. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;855:175–82.CrossRefPubMed
8.
go back to reference Sharma R, Nakamura M, Neupane C, Jeon BH, Shin H, Melnick SM, Glenn KJ, Jang IS, Park JB. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;879: 173117.CrossRefPubMed Sharma R, Nakamura M, Neupane C, Jeon BH, Shin H, Melnick SM, Glenn KJ, Jang IS, Park JB. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;879: 173117.CrossRefPubMed
9.
go back to reference Krauss GL, Klein P, Brandt C, Kun Lee S, Milanov I, Milovanovic M, Steinhoff BJ, Kamin M. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38–48.CrossRefPubMed Krauss GL, Klein P, Brandt C, Kun Lee S, Milanov I, Milovanovic M, Steinhoff BJ, Kamin M. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38–48.CrossRefPubMed
10.
go back to reference Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, Rosenfeld WE, Sperling MR, Mizne S, Kamin M. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311–22.CrossRefPubMedPubMedCentral Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, Rosenfeld WE, Sperling MR, Mizne S, Kamin M. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311–22.CrossRefPubMedPubMedCentral
11.
go back to reference Klein P, Aboumatar S, Brandt C, Dong F, Krauss GL, Mizne S, Sanchez-Alvarez JC, Steinhoff BJ, Villanueva V. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99(10):e989–98.CrossRefPubMedPubMedCentral Klein P, Aboumatar S, Brandt C, Dong F, Krauss GL, Mizne S, Sanchez-Alvarez JC, Steinhoff BJ, Villanueva V. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99(10):e989–98.CrossRefPubMedPubMedCentral
12.
go back to reference Sperling MR, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Klein P, Krauss GL, Vossler DG, Wechsler R, Ferrari L, Kamin M, Grall M, Rosenfeld WE. Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsia. 2021;62(12):3005–15.CrossRefPubMedPubMedCentral Sperling MR, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Klein P, Krauss GL, Vossler DG, Wechsler R, Ferrari L, Kamin M, Grall M, Rosenfeld WE. Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsia. 2021;62(12):3005–15.CrossRefPubMedPubMedCentral
13.
go back to reference Abou-Khalil B, Aboumatar S, Klein P, Krauss GL, Sperling MR, Rosenfeld WE. Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsy Res. 2022;184: 106952.CrossRefPubMed Abou-Khalil B, Aboumatar S, Klein P, Krauss GL, Sperling MR, Rosenfeld WE. Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsy Res. 2022;184: 106952.CrossRefPubMed
14.
go back to reference Lowerison MW, Josephson CB, Jetté N, Sajobi TT, Patten S, Williamson T, Deardon R, Barkema HW, Wiebe S. Association of levels of specialized care with risk of premature mortality in patients with epilepsy. JAMA Neurol. 2019;76(11):1352–8.CrossRefPubMedPubMedCentral Lowerison MW, Josephson CB, Jetté N, Sajobi TT, Patten S, Williamson T, Deardon R, Barkema HW, Wiebe S. Association of levels of specialized care with risk of premature mortality in patients with epilepsy. JAMA Neurol. 2019;76(11):1352–8.CrossRefPubMedPubMedCentral
15.
go back to reference Ostendorf AP, Ahrens SM, Lado FA, Arnold ST, Bai S, Bensalem Owen MK, Chapman KE, Clarke DF, Eisner M, Fountain NB, Gray JM, Hopp JL, Riker E, Schuele SU, Small BV, Herman ST. United States epilepsy center characteristics: a data analysis from the National Association of Epilepsy Centers. Neurology. 2022;98(5):e449–58.CrossRefPubMedPubMedCentral Ostendorf AP, Ahrens SM, Lado FA, Arnold ST, Bai S, Bensalem Owen MK, Chapman KE, Clarke DF, Eisner M, Fountain NB, Gray JM, Hopp JL, Riker E, Schuele SU, Small BV, Herman ST. United States epilepsy center characteristics: a data analysis from the National Association of Epilepsy Centers. Neurology. 2022;98(5):e449–58.CrossRefPubMedPubMedCentral
16.
go back to reference Všianský V, Brázdil M, Rektor I, Doležalová I, Kočvarová J, Strýček O, Hemza J, Chrastina J, Brichtová E, Horák O, Mužlayová P, Hermanová M, Hendrych M, Pail M. Twenty-five years of epilepsy surgery at a Central European comprehensive epilepsy center-trends in intervention delay and outcomes. Epilepsia Open. 2023;8(3):991–1001.CrossRefPubMedPubMedCentral Všianský V, Brázdil M, Rektor I, Doležalová I, Kočvarová J, Strýček O, Hemza J, Chrastina J, Brichtová E, Horák O, Mužlayová P, Hermanová M, Hendrych M, Pail M. Twenty-five years of epilepsy surgery at a Central European comprehensive epilepsy center-trends in intervention delay and outcomes. Epilepsia Open. 2023;8(3):991–1001.CrossRefPubMedPubMedCentral
17.
go back to reference Samanta D, Ostendorf AP, Willis E, Singh R, Gedela S, Arya R, Scott PM. Underutilization of epilepsy surgery: part I: a scoping review of barriers. Epilepsy Behav. 2021;117: 107837.CrossRefPubMedPubMedCentral Samanta D, Ostendorf AP, Willis E, Singh R, Gedela S, Arya R, Scott PM. Underutilization of epilepsy surgery: part I: a scoping review of barriers. Epilepsy Behav. 2021;117: 107837.CrossRefPubMedPubMedCentral
18.
go back to reference Martinez-Juarez IE, Funes B, Moreno-Castellanos JC, Bribiesca-Contreras E, Martinez-Bustos V, Zertuche-Ortuno L, Hernandez-Vanegas LE, Ronquillo LH, Rizvi S, Adam W, Tellez-Zenteno JF. A comparison of waiting times for assessment and epilepsy surgery between a Canadian and a Mexican referral center. Epilepsia Open. 2017;2(4):453–8.CrossRefPubMedPubMedCentral Martinez-Juarez IE, Funes B, Moreno-Castellanos JC, Bribiesca-Contreras E, Martinez-Bustos V, Zertuche-Ortuno L, Hernandez-Vanegas LE, Ronquillo LH, Rizvi S, Adam W, Tellez-Zenteno JF. A comparison of waiting times for assessment and epilepsy surgery between a Canadian and a Mexican referral center. Epilepsia Open. 2017;2(4):453–8.CrossRefPubMedPubMedCentral
19.
go back to reference Pandya V, Bauer P, Thompson S, Anderson CT, Raghavan M, Carlson C. Anti-seizure medication treatment trials prior to pre-surgical evaluation. Epilepsy Behav Rep. 2022;20: 100565.CrossRefPubMedPubMedCentral Pandya V, Bauer P, Thompson S, Anderson CT, Raghavan M, Carlson C. Anti-seizure medication treatment trials prior to pre-surgical evaluation. Epilepsy Behav Rep. 2022;20: 100565.CrossRefPubMedPubMedCentral
20.
go back to reference Steinbrenner M, Kowski AB, Holtkamp M. Referral to evaluation for epilepsy surgery: reluctance by epileptologists and patients. Epilepsia. 2019;60(2):211–9.CrossRefPubMed Steinbrenner M, Kowski AB, Holtkamp M. Referral to evaluation for epilepsy surgery: reluctance by epileptologists and patients. Epilepsia. 2019;60(2):211–9.CrossRefPubMed
21.
go back to reference Jędrzejczak J, Marusic P, Haldre S, Majkowska-Zwolińska B, Bojinova-Tchamova V, Mameniskiene R, Mindruta I, Ravnik IM, Szupera Z, Sykora P, Verzbickis A, Daniluk J. Current status of epilepsy health care for adult patients from central and eastern European Union countries—a survey of members of the Central Europe Epilepsy Experts Working Group. Seizure. 2013;22(6):452–6.CrossRefPubMed Jędrzejczak J, Marusic P, Haldre S, Majkowska-Zwolińska B, Bojinova-Tchamova V, Mameniskiene R, Mindruta I, Ravnik IM, Szupera Z, Sykora P, Verzbickis A, Daniluk J. Current status of epilepsy health care for adult patients from central and eastern European Union countries—a survey of members of the Central Europe Epilepsy Experts Working Group. Seizure. 2013;22(6):452–6.CrossRefPubMed
22.
23.
go back to reference Villanueva V, Santos-Carrasco D, Cabezudo-García P, Gómez-Ibáñez A, Garcés M, Serrano-Castro P, Castro-Vilanova MD, Sayas D, Lopez-Gonzalez FJ, Rodríguez-Osorio X, Torres-Gaona G, Saiz-Diaz RA, Hampel KG, Martinez-Ferri M, Aguilar-Amat MJ, Mercedes-Alvarez B, García-Morales V, Del Villar-Igea A, Massot-Tarrús A, Rodríguez-Uranga JJ. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program. Epilepsia Open. 2023;8(3):918–29.CrossRefPubMedPubMedCentral Villanueva V, Santos-Carrasco D, Cabezudo-García P, Gómez-Ibáñez A, Garcés M, Serrano-Castro P, Castro-Vilanova MD, Sayas D, Lopez-Gonzalez FJ, Rodríguez-Osorio X, Torres-Gaona G, Saiz-Diaz RA, Hampel KG, Martinez-Ferri M, Aguilar-Amat MJ, Mercedes-Alvarez B, García-Morales V, Del Villar-Igea A, Massot-Tarrús A, Rodríguez-Uranga JJ. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program. Epilepsia Open. 2023;8(3):918–29.CrossRefPubMedPubMedCentral
24.
go back to reference Peña-Ceballos J, Moloney PB, Munteanu T, Doyle M, Colleran N, Liggan B, Breen A, Murphy S, El-Naggar H, Widdess-Walsh P, Delanty N. Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a ‘real-world’ retrospective study. Epilepsia. 2023;64:1225–35.CrossRefPubMed Peña-Ceballos J, Moloney PB, Munteanu T, Doyle M, Colleran N, Liggan B, Breen A, Murphy S, El-Naggar H, Widdess-Walsh P, Delanty N. Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a ‘real-world’ retrospective study. Epilepsia. 2023;64:1225–35.CrossRefPubMed
25.
go back to reference Smith MC, Klein P, Krauss GL, Rashid S, Seiden LG, Stern JM, Rosenfeld WE. Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations. Neurol Ther. 2022;11:1705–20.CrossRefPubMedPubMedCentral Smith MC, Klein P, Krauss GL, Rashid S, Seiden LG, Stern JM, Rosenfeld WE. Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations. Neurol Ther. 2022;11:1705–20.CrossRefPubMedPubMedCentral
26.
go back to reference Rosenfeld WE, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Krauss GL, Sperling MR, Vossler DG, Klein P, Wechsler R. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia. 2021;62(12):3016–28.CrossRefPubMedPubMedCentral Rosenfeld WE, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Krauss GL, Sperling MR, Vossler DG, Klein P, Wechsler R. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia. 2021;62(12):3016–28.CrossRefPubMedPubMedCentral
27.
go back to reference Carreño M, Gil-Nagel A, Serratosa JM, Toledo M, Rodriguez-Uranga JJ, Villanueva V. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures. Epilepsia Open. 2024;9:1051–8.CrossRefPubMedPubMedCentral Carreño M, Gil-Nagel A, Serratosa JM, Toledo M, Rodriguez-Uranga JJ, Villanueva V. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures. Epilepsia Open. 2024;9:1051–8.CrossRefPubMedPubMedCentral
28.
go back to reference Aboumatar S, Ferrari L, Stern S, Wade CT, Weingarten M, Connor GS, Rosenfeld WE. Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: post hoc analysis of a subset of patients from a phase 3, multicenter, open-label study. Epilepsy Res. 2024;200: 107306.CrossRefPubMed Aboumatar S, Ferrari L, Stern S, Wade CT, Weingarten M, Connor GS, Rosenfeld WE. Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: post hoc analysis of a subset of patients from a phase 3, multicenter, open-label study. Epilepsy Res. 2024;200: 107306.CrossRefPubMed
Metadata
Title
Presurgical Use of Cenobamate for Adult and Pediatric Patients Referred for Epilepsy Surgery: Expert Panel Recommendations
Authors
Kenneth D. Laxer
Christopher J. Elder
Giancarlo Di Gennaro
Louis Ferrari
Gregory L. Krauss
Jacob Pellinen
William E. Rosenfeld
Vicente Villanueva
Publication date
18-08-2024
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 5/2024
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-024-00651-4

Other articles of this Issue 5/2024

Neurology and Therapy 5/2024 Go to the issue

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more